Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (773)	12/11/2003 6:11:01 AM
From: nigel bates	Read Replies (1) \| Respond to of 2240

Medarex Announces Commencement of Phase I Clinical Trials by Centocor of Anti-Angiogenesis Antibody, CNTO 95 Thursday December 11, 6:00 am ET Preclinical Data Indicates Inhibition of Tumor Growth and Tumor-Induced Angiogenesis PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that its licensing partner, Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson, has commenced a multi-dose Phase I clinical trial of CNTO 95, a fully human antibody targeting the integrin receptors that are implicated in tumor-induced angiogenesis. Angiogenesis is the formation of new blood vessels and plays an important role in tumor growth and metastasis. Preclinical data presented by Centocor at the 94th annual meeting of the American Association for Cancer Research (AACR) indicated that blockade of the integrin receptors by CNTO 95 inhibited the growth of new blood vessels in vitro and also inhibited growth of human melanoma tumors in nude mice (Abstract #754). CNTO 95 was generated at Centocor using Medarex's UltiMAb(TM) technology and is the third UltiMAb-derived antibody in clinical development by Centocor and the fourteenth UltiMAb product being tested in human clinical trials. Medarex is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating diseases. Medarex's UltiMAb Human Antibody Development System® is a unique combination of human antibody technologies that Medarex believes enables the rapid creation and development of fully human antibodies to a wide range of potential disease targets for therapeutic antibody products, including products for the treatment of cancer, inflammation, autoimmune and infectious diseases. Medarex's product pipeline is based on a variety of therapeutic antibody products developed through the use of its UltiMAb(TM) technology. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services. For more information about Medarex, visit its website at www.medarex.com...